As of Oct 20
| -0.04 / -2.12%|
The 3 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 19.50, with a high estimate of 20.00 and a low estimate of 13.00. The median estimate represents a +954.05% increase from the last price of 1.85.
The current consensus among 3 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.